Bone Marrow Transplant   

Is there a role for non-myeloablative regimens?

What criteria do you use to define steroid-refractory disease? Does your management different by organ system involved - GI vs skin vs other?

How do you choose between RIC compared to MAC? Is there evidence for one over the other in an otherwise healthy, young patient? Do you include hypome...

NCCN says "consider autologous HCT" while retrospective data seems to support SCT in most histologies like AITL

Have you changed your practice given BMT-CTN 1506/Morpho results? Would you utilize maintenance therapy in patients who achieve MRD- remission?

How does graft source, conditioning regimen, and indication for transplant affect your decision regarding G-CSF?

Would you test for bone marrow failure syndromes before beginning the conditioning regimen?

What would your next line therapy be? If the patient had no matched related or unrelated donors, would you consider haploidentical transplant?

Presuming there are no matched unrelated donors.

If not, how do you choose GVHD prophylaxis regimen? Is there a preference?

How does graft function play into your decision making? How do you utilize post allogeneic transplant chimerism in clinical practice? Do you obta...

How does belumosudil now fit in your approach to steroid refractory chronic graft-versus-host disease?

Are there major differences in standard conditioning and/or GVHD prophylaxis regimens utilized? Does the non-relapse mortality different significantl...

Such as patients who are frail, elderly, renally impaired? Would you consider sirolimus over cyclosporine or tacrolimus for safer nephrotoxicity prof...

If given both options, which donor would one prefer: haploidentical related donor or 7/8 mismatched unrelated donor using post transplant cyclophospha...

Both the patient's nasopharyngeal swab and stem cells themselves resulted COVID positive post-harvesting.

Adults tend to do this procedure earlier in the course, but it is unclear when it is appropriate for a pediatric patient, and is often considered too ...

Do you always treat with the full 21-day treatment course, or can defibrotide be stopped if certain criteria are met sooner?

Or do you use prophylactic defibrotide?

I have heard <20% MRD. What about proceeding if patient is hypoplastic after chemotherapy?

Would you consider “bridging” therapy with something like an HMA?

What dose do you recommend?